Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada.
Jason K LeeSuvina AminMichelle ErdmannAtif KukaswadiaJelena IvanovicAren FischerAlain GendronPublished in: Patient preference and adherence (2020)
Nearly one-third of patients who initiated omalizumab in Canada for refractory, moderate to severe allergic asthma discontinued treatment during the first year.